Sandra Horning, MD
Combination therapy with the PD-L1 inhibitor atezolizumab (Tecentriq) and the MEK inhibitor cobimetinib (Cotellic) failed to improve overall survival (OS) versus regorafenib (Stivarga) in previous treated patients with locally advanced or metastatic colorectal cancer (CRC), according to topline findings from the phase III IMblaze370 study.
wild-type, and the status of 2 patients was unknown. Sixty-six (79%) had received ≥5 previous systemic therapies.
... to read the full story